Displaying drugs 5101 - 5125 of 5886 in total
Mirdametinib
PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.
Investigational
Bioymifi
Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic. Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.[A257048,A257053]
Investigational
Furo[2,3d]Pyrimidine Antifolate
Experimental
5-(2,5-DICHLOROPHENYL)-2-FUROIC ACID
Experimental
Naproxcinod
Investigational
Apricitabine
Apricitabine has been used in trials studying the treatment of HIV Infections.
Investigational
Royal jelly
Royal jelly is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Vicriviroc
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
Investigational
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. [PubChem]
Experimental
3-(2-Benzothiazolylthio)-1-Propanesulfonic Acid
Experimental
D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
Experimental
G4460
Investigational
Irpagratinib
Irpagratinib (ABSK011) is a highly selective inhibitor of fibroblast growth factor receptor (FGFR) 4.
Investigational
PMC-403
PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.
Investigational
Displaying drugs 5101 - 5125 of 5886 in total